Impact of FcγR variants on the response to alemtuzumab in multiple sclerosis

Allelic variants of genes encoding for the Fc gamma receptors IIIA and IIA have been associated with the clinical response to cell‐depleting antibodies in lymphoma patients. Here, we tested the hypothesis that FCGR3A and FCGR2A high‐affinity polymorphisms predict clinical outcomes to alemtuzumab the...

Descripción completa

Detalles Bibliográficos
Autores principales: Keller, Christian W., Ruck, Tobias, McHugh, Donal, Pfeuffer, Steffen, Gross, Catharina C., Korsukewitz, Catharina, Melzer, Nico, Klotz, Luisa, Meuth, Sven G., Münz, Christian, Nimmerjahn, Falk, Wiendl, Heinz, Lünemann, Jan D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Brief Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6917309/
https://www.ncbi.nlm.nih.gov/pubmed/31682087
http://dx.doi.org/10.1002/acn3.50935
_version_ 1783480388015882240
author Keller, Christian W.
Ruck, Tobias
McHugh, Donal
Pfeuffer, Steffen
Gross, Catharina C.
Korsukewitz, Catharina
Melzer, Nico
Klotz, Luisa
Meuth, Sven G.
Münz, Christian
Nimmerjahn, Falk
Wiendl, Heinz
Lünemann, Jan D.
author_facet Keller, Christian W.
Ruck, Tobias
McHugh, Donal
Pfeuffer, Steffen
Gross, Catharina C.
Korsukewitz, Catharina
Melzer, Nico
Klotz, Luisa
Meuth, Sven G.
Münz, Christian
Nimmerjahn, Falk
Wiendl, Heinz
Lünemann, Jan D.
author_sort Keller, Christian W.
collection PubMed
description Allelic variants of genes encoding for the Fc gamma receptors IIIA and IIA have been associated with the clinical response to cell‐depleting antibodies in lymphoma patients. Here, we tested the hypothesis that FCGR3A and FCGR2A high‐affinity polymorphisms predict clinical outcomes to alemtuzumab therapy in 85 patients with relapsing‐remitting multiple sclerosis. No differences in clinical and MRI‐based efficacy parameters, the development of severe infusion‐associated reactions and secondary autoimmune diseases during a 2 year follow‐up was observed based on FCGR3A or FCGR2A polymorphisms. This study does not support the use of FCGR genetic variants to predict clinical outcomes to alemtuzumab.
format Online
Article
Text
id pubmed-6917309
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-69173092019-12-23 Impact of FcγR variants on the response to alemtuzumab in multiple sclerosis Keller, Christian W. Ruck, Tobias McHugh, Donal Pfeuffer, Steffen Gross, Catharina C. Korsukewitz, Catharina Melzer, Nico Klotz, Luisa Meuth, Sven G. Münz, Christian Nimmerjahn, Falk Wiendl, Heinz Lünemann, Jan D. Ann Clin Transl Neurol Brief Communications Allelic variants of genes encoding for the Fc gamma receptors IIIA and IIA have been associated with the clinical response to cell‐depleting antibodies in lymphoma patients. Here, we tested the hypothesis that FCGR3A and FCGR2A high‐affinity polymorphisms predict clinical outcomes to alemtuzumab therapy in 85 patients with relapsing‐remitting multiple sclerosis. No differences in clinical and MRI‐based efficacy parameters, the development of severe infusion‐associated reactions and secondary autoimmune diseases during a 2 year follow‐up was observed based on FCGR3A or FCGR2A polymorphisms. This study does not support the use of FCGR genetic variants to predict clinical outcomes to alemtuzumab. John Wiley and Sons Inc. 2019-11-04 /pmc/articles/PMC6917309/ /pubmed/31682087 http://dx.doi.org/10.1002/acn3.50935 Text en © 2019 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Brief Communications
Keller, Christian W.
Ruck, Tobias
McHugh, Donal
Pfeuffer, Steffen
Gross, Catharina C.
Korsukewitz, Catharina
Melzer, Nico
Klotz, Luisa
Meuth, Sven G.
Münz, Christian
Nimmerjahn, Falk
Wiendl, Heinz
Lünemann, Jan D.
Impact of FcγR variants on the response to alemtuzumab in multiple sclerosis
title Impact of FcγR variants on the response to alemtuzumab in multiple sclerosis
title_full Impact of FcγR variants on the response to alemtuzumab in multiple sclerosis
title_fullStr Impact of FcγR variants on the response to alemtuzumab in multiple sclerosis
title_full_unstemmed Impact of FcγR variants on the response to alemtuzumab in multiple sclerosis
title_short Impact of FcγR variants on the response to alemtuzumab in multiple sclerosis
title_sort impact of fcγr variants on the response to alemtuzumab in multiple sclerosis
topic Brief Communications
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6917309/
https://www.ncbi.nlm.nih.gov/pubmed/31682087
http://dx.doi.org/10.1002/acn3.50935
work_keys_str_mv AT kellerchristianw impactoffcgrvariantsontheresponsetoalemtuzumabinmultiplesclerosis
AT rucktobias impactoffcgrvariantsontheresponsetoalemtuzumabinmultiplesclerosis
AT mchughdonal impactoffcgrvariantsontheresponsetoalemtuzumabinmultiplesclerosis
AT pfeuffersteffen impactoffcgrvariantsontheresponsetoalemtuzumabinmultiplesclerosis
AT grosscatharinac impactoffcgrvariantsontheresponsetoalemtuzumabinmultiplesclerosis
AT korsukewitzcatharina impactoffcgrvariantsontheresponsetoalemtuzumabinmultiplesclerosis
AT melzernico impactoffcgrvariantsontheresponsetoalemtuzumabinmultiplesclerosis
AT klotzluisa impactoffcgrvariantsontheresponsetoalemtuzumabinmultiplesclerosis
AT meuthsveng impactoffcgrvariantsontheresponsetoalemtuzumabinmultiplesclerosis
AT munzchristian impactoffcgrvariantsontheresponsetoalemtuzumabinmultiplesclerosis
AT nimmerjahnfalk impactoffcgrvariantsontheresponsetoalemtuzumabinmultiplesclerosis
AT wiendlheinz impactoffcgrvariantsontheresponsetoalemtuzumabinmultiplesclerosis
AT lunemannjand impactoffcgrvariantsontheresponsetoalemtuzumabinmultiplesclerosis

Ejemplares similares